These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 30532532)

  • 1. Regulation of in vivo behavior of TAT-modified liposome by associated protein corona and avidity to tumor cells.
    Amin M; Bagheri M; Mansourian M; Jaafari MR; Ten Hagen TL
    Int J Nanomedicine; 2018; 13():7441-7455. PubMed ID: 30532532
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tat peptide and hexadecylphosphocholine introduction into pegylated liposomal doxorubicin: An in vitro and in vivo study on drug cellular delivery, release, biodistribution and antitumor activity.
    Teymouri M; Badiee A; Golmohammadzadeh S; Sadri K; Akhtari J; Mellat M; Nikpoor AR; Jaafari MR
    Int J Pharm; 2016 Sep; 511(1):236-244. PubMed ID: 27363937
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Study of FA12 peptide-modified PEGylated liposomal doxorubicin (PLD) as an effective ligand to target Muc1 in mice bearing C26 colon carcinoma: in silico, in vitro, and in vivo study.
    Biabangard A; Asoodeh A; Jaafari MR; Mashreghi M
    Expert Opin Drug Deliv; 2022 Dec; 19(12):1710-1724. PubMed ID: 36373415
    [TBL] [Abstract][Full Text] [Related]  

  • 4. pH-Sensitive PEGylated Liposomal Silybin: Synthesis, In Vitro and In Vivo Anti-Tumor Evaluation.
    Gheybi F; Alavizadeh SH; Rezayat SM; Hatamipour M; Akhtari J; Faridi Majidi R; Badiee A; Jaafari MR
    J Pharm Sci; 2021 Dec; 110(12):3919-3928. PubMed ID: 34418455
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of pharmacokinetic and antitumor activity of PEGylated liposomal doxorubicin by targeting with N-methylated cyclic RGD peptide in mice bearing C-26 colon carcinomas.
    Amin M; Badiee A; Jaafari MR
    Int J Pharm; 2013 Dec; 458(2):324-33. PubMed ID: 24148663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doxorubicin in TAT peptide-modified multifunctional immunoliposomes demonstrates increased activity against both drug-sensitive and drug-resistant ovarian cancer models.
    Apte A; Koren E; Koshkaryev A; Torchilin VP
    Cancer Biol Ther; 2014 Jan; 15(1):69-80. PubMed ID: 24145298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic efficacy of combining pegylated liposomal doxorubicin and radiofrequency (RF) ablation: comparison between slow-drug-releasing, non-thermosensitive and fast-drug-releasing, thermosensitive nano-liposomes.
    Andriyanov AV; Koren E; Barenholz Y; Goldberg SN
    PLoS One; 2014; 9(5):e92555. PubMed ID: 24786533
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Translocation of liposomes into cancer cells by cell-penetrating peptides penetratin and tat: a kinetic and efficacy study.
    Tseng YL; Liu JJ; Hong RL
    Mol Pharmacol; 2002 Oct; 62(4):864-72. PubMed ID: 12237333
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Improving anti-tumour efficacy of PEGylated liposomal doxorubicin by dual targeting of tumour cells and tumour endothelial cells using anti-p32 CGKRK peptide.
    Mashreghi M; Faal Maleki M; Karimi M; Kalalinia F; Badiee A; Jaafari MR
    J Drug Target; 2021 Jul; 29(6):617-630. PubMed ID: 33393376
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Folate and TAT peptide co-modified liposomes exhibit receptor-dependent highly efficient intracellular transport of payload in vitro and in vivo.
    Zhu Y; Cheng L; Cheng L; Huang F; Hu Q; Li L; Tian C; Wei L; Chen D
    Pharm Res; 2014 Dec; 31(12):3289-303. PubMed ID: 24858397
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and characterization of PEGylated liposomal Doxorubicin targeted with leptin-derived peptide and evaluation of their anti-tumor effects, in vitro and in vivo in mice bearing C26 colon carcinoma.
    Shahraki N; Mehrabian A; Amiri-Darban S; Moosavian SA; Jaafari MR
    Colloids Surf B Biointerfaces; 2021 Apr; 200():111589. PubMed ID: 33545570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative effects of free doxorubicin, liposome encapsulated doxorubicin and liposome co-encapsulated alendronate and doxorubicin (PLAD) on the tumor immunologic milieu in a mouse fibrosarcoma model.
    Islam MR; Patel J; Back PI; Shmeeda H; Adamsky K; Yang H; Alvarez C; Gabizon AA; La-Beck NM
    Nanotheranostics; 2022; 6(4):451-464. PubMed ID: 36105861
    [No Abstract]   [Full Text] [Related]  

  • 13. Glycyrrhetinic Acid and TAT Peptide Modified Dual-functional Liposomes for Treatment of Hepatocellular Cancer.
    Huang S; Ren D; Wu X; Li M; Yu X; Nie X; Wang Y; Wang Y
    Curr Top Med Chem; 2020; 20(27):2493-2505. PubMed ID: 32703132
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The role of size in PEGylated liposomal doxorubicin biodistribution and anti-tumour activity.
    Dadpour S; Mehrabian A; Arabsalmani M; Mirhadi E; Askarizadeh A; Mashreghi M; Jaafari MR
    IET Nanobiotechnol; 2022 Sep; 16(7-8):259-272. PubMed ID: 35983586
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a novel cyclic RGD peptide for multiple targeting approaches of liposomes to tumor region.
    Amin M; Mansourian M; Koning GA; Badiee A; Jaafari MR; Ten Hagen TLM
    J Control Release; 2015 Dec; 220(Pt A):308-315. PubMed ID: 26526970
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Her2-targeted pegylated liposomal doxorubicin: retention of target-specific binding and cytotoxicity after in vivo passage.
    Shmeeda H; Tzemach D; Mak L; Gabizon A
    J Control Release; 2009 Jun; 136(2):155-60. PubMed ID: 19331844
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy?
    Cui J; Li C; Guo W; Li Y; Wang C; Zhang L; Zhang L; Hao Y; Wang Y
    J Control Release; 2007 Apr; 118(2):204-15. PubMed ID: 17239468
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A liposomal drug platform overrides peptide ligand targeting to a cancer biomarker, irrespective of ligand affinity or density.
    Gray BP; McGuire MJ; Brown KC
    PLoS One; 2013; 8(8):e72938. PubMed ID: 24009717
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Increased delivery of doxorubicin into tumor cells using extracellularly activated TAT functionalized liposomes: in vitro and in vivo study.
    Yuan W; Kuai R; Ran R; Fu L; Yang Y; Qin Y; Liu Y; Tang J; Fu H; Zhang Q; Yuan M; Zhang Z; Gao F; He Q
    J Biomed Nanotechnol; 2014 Aug; 10(8):1563-73. PubMed ID: 25016656
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased Targeting Area in Tumors by Dual-Ligand Modification of Liposomes with RGD and TAT Peptides.
    Amin M; Mansourian M; Burgers PC; Amin B; Jaafari MR; Ten Hagen TLM
    Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214190
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.